Developer docs
API playgroundTry for free, no card

Search company profiles

Inimmune

Full company profile

uuid0000pf3

Namestring
Inimmune
Legal namestring
Inimmune Corporation
Websiteurl
inimmune.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Inimmune Corporation is a privately held, clinical-stage biotechnology company founded in 2016 in Missoula, Montana, by a team of former GSK Vaccines scientists. The company is developing a portfolio of disease-modifying immunotherapies and vaccine adjuvants built around proprietary synthetic agonists of innate immune receptors — primarily Toll-like receptors (TLR4, TLR7/8), Mincle, and STING — formulated in proprietary nanoparticle and adjuvant systems. Its lead clinical asset, INI-2004 (intranasal TLR4 agonist), has completed Phase 1 for allergic rhinitis and entered a pivotal Phase 2 allergen chamber trial in early 2026; the second clinical asset, INI-4001 (TLR7/8 agonist in a proprietary nanoparticle), is in Phase 1 for solid tumors, both as monotherapy and in combination with checkpoint inhibitors. The company is also advancing a deep pre-clinical and translational pipeline including the anti-opioid vaccine program (NIH HEAL), the Mincle-agonist INI-1098 for tuberculosis (NIH contract), the combination adjuvant TRAC478, and the T4Q/T4AH adjuvant systems partnered with SPI Pharma.

Inimmune is pre-revenue and operates a partnership-and-licensing business model: monetization is expected through co-development agreements, out-licensing of pipeline assets, milestone payments, and ultimately commercial supply of adjuvant systems to pharmaceutical partners, supplemented by substantial non-dilutive NIH funding (~$34M HEAL contract, $12.3M TB adjuvant contract, up to $9M NIAID contract). The company raised a $22 million Series A in July 2020 led by Two Bear Capital (the largest Series A in Montana history) and has since been actively seeking a Series A extension. The company maintains 11–50 employees at its Montana headquarters, has appointed a new CMO (Dr. Ferdinand Massari) and Head of Financial Strategy (Ryan McMillian) in March 2026 ahead of the INI-2004 Phase 2 readout, and is presently expanding into European consortia (EU4Health intranasal influenza vaccine) while broadening its allergy franchise from allergic rhinitis into food allergies and allergic asthma.

Short descriptiontext

Inimmune is a clinical-stage, privately held biotech developing disease-modifying immunotherapies and vaccine adjuvants based on proprietary synthetic TLR, Mincle, and STING agonists, with lead programs INI-2004 in Phase 2 for allergic rhinitis and INI-4001 in Phase 1 for solid tumors, targeting pharma partners via licensing and co-development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMissoula, United States
HQ citystring
Missoula
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
TLR agonist immunotherapeutics, vaccine adjuvant systems, innate immune modulation, allergy immunotherapy development, cancer immunotherapy pipelines
Industry4 codes
PRIMARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Immunotherapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Co-development Agreements
TypeLicensing Royalties
Description

Pre-revenue clinical stage company with no commercial products. Revenue will be generated through licensing deals, co-development partnerships, and milestone payments with pharmaceutical partners. The company is actively seeking Series A extension investors.

inimmune.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Inimmune is a clinical-stage biotechnology company developing a portfolio of disease-modifying immunotherapies and vaccine adjuvants based on proprietary Toll-like receptor (TLR) agonist technology. The company focuses on innate immune system modulation, with clinical-stage assets including INI-2004 (TLR4 agonist for allergic rhinitis) and INI-4001 (TLR7/8 agonist for cancer immunotherapy), plus advanced adjuvant systems (T4Q, T4AH, TRAC478, INI-1098) and vaccine candidates targeting opioid use disorder and infectious diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase I trial: 53% improvement in nasal volume post ragweed challenge at 500µg dose vs placebo
+2 more records
Product overview1 text field

Inimmune is a clinical-stage biotechnology company developing a portfolio of disease-modifying immunotherapies and vaccine adjuvants. The core products include INI-2004 (TLR4 agonist for allergic rhinitis, positioned as a pipeline-in-a-product with expansion potential into food allergies and allergic asthma) and INI-4001 (TLR7/8 agonist for cancer immunotherapy with dual use as vaccine adjuvant). The company also commercializes advanced adjuvant systems (T4Q, T4AH, TRAC478) through its SPI Pharma partnership and develops pre-clinical vaccine candidates for opioid addiction and infectious diseases. The portfolio is anchored on innate immune system modulation targeting TLRs, Mincle, and STING pathways.

Product and service6 records
1INI-2004
CategoryAllergy Immunotherapy
Description

Allergen-agnostic immunotherapy targeting toll-like receptor 4 (TLR4) delivered as an intranasal spray for rapid disease-modifying treatment of allergic rhinitis; positioned as a pipeline-in-a-product with planned expansion into food allergies and allergic asthma. Currently in Phase 2 clinical trials.

2INI-4001
CategoryCancer Immunotherapy
Description

Synthetic TLR7/8 agonist formulated in a proprietary clinical nanoparticle for cancer immunotherapy; also used as a vaccine adjuvant for opioid and influenza vaccines. Engineered to stimulate innate immune pathways with potential as both monotherapy and in combination with checkpoint inhibitors for solid tumors.

3TRAC478
CategoryVaccine Adjuvant
Description

Combination adjuvant combining INI-2002 (TLR4 agonist) and INI-4001 (TLR7/8 agonist) designed to generate synergistic immune responses; produces strong Th1-biased antibody and T cell responses efficacious in influenza challenge models.

4INI-1098
CategoryVaccine Adjuvant
Description

Novel synthetic Mincle agonist developed as a Th17-generating adjuvant for bacterial and fungal pathogens including tuberculosis; manufactured under cGMP via an NIH-funded Adjuvant Development Contract.

5T4Q Adjuvant System
CategoryVaccine Adjuvant System
Description

Advanced adjuvant system combining INI-2002 (TLR4 agonist) with QS21 saponin; partnered with SPI Pharma for commercialization; offers improved stability and immunogenicity over current clinical TLR4 + saponin combinations.

6T4AH Adjuvant System
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-01
Description

Partnership to develop and commercialize innovative vaccine adjuvant systems (T4Q and T4AH). SPI Pharma specializes in drug development services with over 60 commercially launched drugs globally. Collaboration focused on delivering affordable and accessible adjuvant systems.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-24
Description

Collaboration on adjuvant discovery and development projects with Drs. Ofer Levy and David Dowling. Current projects focused on development of adjuvanted opioid and pertussis vaccines. Supported by NIH/NIAID Vaccine Adjuvant Development Program contract up to $9 million over 5 years.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing collaboration with Dr. Ted Ross at Cleveland Clinic working on developing an adjuvanted universal influenza vaccine.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Sandra Comer at Columbia University for opioid vaccine development efforts. Dr. Comer is a leader in opioid vaccine clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Drs. Herman Staats and Brandi Johnson-Weaver at Duke for development of sublingual food allergy treatment using INI-2004 as an adjuvant.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Drs. Florian Krammer and Adolfo Garcia-Sastre on multiple projects focused on developing new adjuvanted influenza vaccines.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development of adjuvanted food allergy treatment combining INI-2004 with Intrommune's clinical-stage oral mucosal immunotherapy INT301 for peanut allergy. Collaboration to evaluate combining the two clinical-stage immunotherapies for rapid and long-term relief.

8Oregon Health Science University (OHSU)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Victor DeFilippis on STING adjuvant discovery project at OHSU.

inimmune.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Aaron Esser-Kahn on discovering novel combination adjuvants. Academic-industry partnership to develop next-generation vaccine adjuvants.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Center for Translational Medicine Adjuvant Research Team on multiple projects including opioid vaccine, TRAC478 vaccine adjuvant, and INI-1098 vaccine adjuvant development projects.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Drs. Mike Kulis and Johanna Smeekens at UNC on development of sublingual food allergy therapy.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Marco Pravetoni on opioid vaccine development project and Dr. Michael Gale on early-stage adjuvant discovery project.

13Medical University of Vienna
Strategic tierCoreTypeStrategic or Co-development Partner
Description

European consortium led by Medical University of Vienna to develop next-generation intranasal influenza vaccine. Consortium aims to be selected under EU4Health programme with budget of EUR 147,951,410. Inimmune contributes proprietary adjuvant INI-4001 and formulation expertise.

inimmune.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dynavax is a commercial-stage biopharmaceutical company focused on vaccines and adjuvants, with the CpG 1018 TLR9 adjuvant platform used in approved COVID and hepatitis B vaccines. Most directly comparable to Inimmune's TLR-based adjuvant business and vaccine development focus.

TypeDirect peer
Description

Adjuvance Technologies is a privately-held biotechnology company developing saponin-based adjuvants including TQL1055, a next-generation semi-synthetic saponin. Directly competes with Inimmune's T4Q (TLR4 + QS21 saponin) and T4AH adjuvant systems in the vaccine adjuvant market.

3Selecta Biosciences
TypeDirect peer
Description

Selecta Biosciences (now Cartesian Therapeutics) developed immune tolerance therapies and novel adjuvants using nanoparticle technology. Comparable to Inimmune in focusing on innate immune modulation and tolerogenic immunotherapies, though focused on autoimmune applications.

TypeEmerging player
Description

Checkmate Pharmaceuticals developed CMP-001, a TLR9 agonist intratumoral therapy for melanoma before being acquired by Regeneron in 2022. Directly relevant precedent for TLR agonist development in oncology immunotherapy, similar to Inimmune's INI-4001 program.

TypeDirect peer
Description

Intrommune Therapeutics is a clinical-stage biotech developing INT301 oral mucosal immunotherapy for peanut and other food allergies. Direct partner with Inimmune combining INI-2004 with INT301 for next-generation allergy treatment.

TypeEmerging player
Description

Bolt Biotherapeutics developed immune-stimulating antibody conjugates (ISACs) targeting innate immunity for cancer treatment. Comparable clinical-stage oncology immunotherapy company using novel immune activation approaches, though with different mechanism than Inimmune's TLR agonists.

TypeBroad incumbent
Description

GSK is a global pharmaceutical leader with the established AS01, AS04, and other proprietary adjuvant systems used in Shingrix, Cervarix, and other vaccines. Inimmune's founders came from GSK Vaccines and compete directly in the adjuvant space with this industry incumbent.

TypeBroad incumbent
Description

Novavax develops recombinant protein vaccines using its proprietary Matrix-M saponin-based adjuvant, comparable to Inimmune's T4Q and T4AH adjuvant systems. Broad incumbent in the vaccine adjuvant and development space.

TypeEmerging player
Description

CureVac is a clinical-stage biopharmaceutical company developing mRNA-based vaccines and immunotherapies with proprietary adjuvant approaches. Comparable clinical-stage biotech developing novel vaccine technology, though using different mRNA platform.

TypeBroad incumbent
Description

Stallergenes Greer is a global leader in allergen immunotherapy (AIT) for respiratory allergies, offering subcutaneous and sublingual treatments. Competes in the allergy immunotherapy market where Inimmune's INI-2004 is positioned as a disease-modifying alternative.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inimmune

Biopharmaceutical Immunotherapeuticsinimmune.com

Inimmune is a clinical-stage, privately held biotech developing disease-modifying immunotherapies and vaccine adjuvants based on proprietary synthetic TLR, Mincle, and STING agonists, with lead programs INI-2004 in Phase 2 for allergic rhinitis and INI-4001 in Phase 1 for solid tumors, targeting pharma partners via licensing and co-development.

What Inimmune does

Inimmune Corporation is a privately held, clinical-stage biotechnology company founded in 2016 in Missoula, Montana, by a team of former GSK Vaccines scientists. The company is developing a portfolio of disease-modifying immunotherapies and vaccine adjuvants built around proprietary synthetic agonists of innate immune receptors — primarily Toll-like receptors (TLR4, TLR7/8), Mincle, and STING — formulated in proprietary nanoparticle and adjuvant systems. Its lead clinical asset, INI-2004 (intranasal TLR4 agonist), has completed Phase 1 for allergic rhinitis and entered a pivotal Phase 2 allergen chamber trial in early 2026; the second clinical asset, INI-4001 (TLR7/8 agonist in a proprietary nanoparticle), is in Phase 1 for solid tumors, both as monotherapy and in combination with checkpoint inhibitors. The company is also advancing a deep pre-clinical and translational pipeline including the anti-opioid vaccine program (NIH HEAL), the Mincle-agonist INI-1098 for tuberculosis (NIH contract), the combination adjuvant TRAC478, and the T4Q/T4AH adjuvant systems partnered with SPI Pharma.

Inimmune is pre-revenue and operates a partnership-and-licensing business model: monetization is expected through co-development agreements, out-licensing of pipeline assets, milestone payments, and ultimately commercial supply of adjuvant systems to pharmaceutical partners, supplemented by substantial non-dilutive NIH funding (~$34M HEAL contract, $12.3M TB adjuvant contract, up to $9M NIAID contract). The company raised a $22 million Series A in July 2020 led by Two Bear Capital (the largest Series A in Montana history) and has since been actively seeking a Series A extension. The company maintains 11–50 employees at its Montana headquarters, has appointed a new CMO (Dr. Ferdinand Massari) and Head of Financial Strategy (Ryan McMillian) in March 2026 ahead of the INI-2004 Phase 2 readout, and is presently expanding into European consortia (EU4Health intranasal influenza vaccine) while broadening its allergy franchise from allergic rhinitis into food allergies and allergic asthma.

Inimmune firmographics

Firmographics
Name
Inimmune
Legal name
Inimmune Corporation
Website
https://inimmune.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Inimmune is a clinical-stage, privately held biotech developing disease-modifying immunotherapies and vaccine adjuvants based on proprietary synthetic TLR, Mincle, and STING agonists, with lead programs INI-2004 in Phase 2 for allergic rhinitis and INI-4001 in Phase 1 for solid tumors, targeting pharma partners via licensing and co-development.
Ownership category
akta.pro rank

Inimmune industry classification

Industry
Product category
Biopharmaceutical Immunotherapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • TLR agonist immunotherapeutics
  • Vaccine adjuvant systems
  • Innate immune modulation
  • Allergy immunotherapy development
  • Cancer immunotherapy pipelines

Where Inimmune is headquartered

Location

Headquarters

HQ city
Missoula
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Inimmune business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Licensing and Co-development Agreements: Pre-revenue clinical stage company with no commercial products. Revenue will be generated through licensing deals, co-development partnerships, and milestone payments with pharmaceutical partners. The company is actively seeking Series A extension investors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Inimmune product offering

Product offering

Core offering

Inimmune is a clinical-stage biotechnology company developing a portfolio of disease-modifying immunotherapies and vaccine adjuvants based on proprietary Toll-like receptor (TLR) agonist technology. The company focuses on innate immune system modulation, with clinical-stage assets including INI-2004 (TLR4 agonist for allergic rhinitis) and INI-4001 (TLR7/8 agonist for cancer immunotherapy), plus advanced adjuvant systems (T4Q, T4AH, TRAC478, INI-1098) and vaccine candidates targeting opioid use disorder and infectious diseases.

Product overview

Inimmune is a clinical-stage biotechnology company developing a portfolio of disease-modifying immunotherapies and vaccine adjuvants. The core products include INI-2004 (TLR4 agonist for allergic rhinitis, positioned as a pipeline-in-a-product with expansion potential into food allergies and allergic asthma) and INI-4001 (TLR7/8 agonist for cancer immunotherapy with dual use as vaccine adjuvant). The company also commercializes advanced adjuvant systems (T4Q, T4AH, TRAC478) through its SPI Pharma partnership and develops pre-clinical vaccine candidates for opioid addiction and infectious diseases. The portfolio is anchored on innate immune system modulation targeting TLRs, Mincle, and STING pathways.

Differentiator

Problem solved

Functional benefit

Products and services

  • INI-2004 Allergen-agnostic immunotherapy targeting toll-like receptor 4 (TLR4) delivered as an intranasal spray for rapid disease-modifying treatment of allergic rhinitis; positioned as a pipeline-in-a-product with planned expansion into food allergies and allergic asthma. Currently in Phase 2 clinical trials.
  • INI-4001 Synthetic TLR7/8 agonist formulated in a proprietary clinical nanoparticle for cancer immunotherapy; also used as a vaccine adjuvant for opioid and influenza vaccines. Engineered to stimulate innate immune pathways with potential as both monotherapy and in combination with checkpoint inhibitors for solid tumors.
  • TRAC478 Combination adjuvant combining INI-2002 (TLR4 agonist) and INI-4001 (TLR7/8 agonist) designed to generate synergistic immune responses; produces strong Th1-biased antibody and T cell responses efficacious in influenza challenge models.
  • INI-1098 Novel synthetic Mincle agonist developed as a Th17-generating adjuvant for bacterial and fungal pathogens including tuberculosis; manufactured under cGMP via an NIH-funded Adjuvant Development Contract.
  • T4Q Adjuvant System Advanced adjuvant system combining INI-2002 (TLR4 agonist) with QS21 saponin; partnered with SPI Pharma for commercialization; offers improved stability and immunogenicity over current clinical TLR4 + saponin combinations.
  • T4AH Adjuvant System

Quantifiable outcome

  • Phase I trial: 53% improvement in nasal volume post ragweed challenge at 500µg dose vs placebo
  • +2 more outcomes

Companies that use Inimmune

Customer profile

Segments3 records

Ideal customer profiles3 records

Inimmune technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Inimmune partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • SPI Pharma, Inc.coreStrategic or Co-development Partner · 1 July 2024Partnership to develop and commercialize innovative vaccine adjuvant systems (T4Q and T4AH). SPI Pharma specializes in drug development services with over 60 commercially launched drugs globally. Collaboration focused on delivering affordable and accessible adjuvant systems.
  • Boston Children's HospitalcoreStrategic or Co-development Partner · 24 October 2023Collaboration on adjuvant discovery and development projects with Drs. Ofer Levy and David Dowling. Current projects focused on development of adjuvanted opioid and pertussis vaccines. Supported by NIH/NIAID Vaccine Adjuvant Development Program contract up to $9 million over 5 years.
  • Cleveland CliniccoreStrategic or Co-development PartnerLong-standing collaboration with Dr. Ted Ross at Cleveland Clinic working on developing an adjuvanted universal influenza vaccine.
  • Columbia UniversitycoreStrategic or Co-development PartnerCollaboration with Dr. Sandra Comer at Columbia University for opioid vaccine development efforts. Dr. Comer is a leader in opioid vaccine clinical trials.
  • Duke UniversitycoreStrategic or Co-development PartnerCollaboration with Drs. Herman Staats and Brandi Johnson-Weaver at Duke for development of sublingual food allergy treatment using INI-2004 as an adjuvant.
  • Icahn School of Medicine at Mount SinaicoreStrategic or Co-development PartnerCollaboration with Drs. Florian Krammer and Adolfo Garcia-Sastre on multiple projects focused on developing new adjuvanted influenza vaccines.
  • Intrommune Therapeutics, Inc.coreStrategic or Co-development PartnerCo-development of adjuvanted food allergy treatment combining INI-2004 with Intrommune's clinical-stage oral mucosal immunotherapy INT301 for peanut allergy. Collaboration to evaluate combining the two clinical-stage immunotherapies for rapid and long-term relief.
  • Oregon Health Science University (OHSU)minorStrategic or Co-development PartnerCollaboration with Dr. Victor DeFilippis on STING adjuvant discovery project at OHSU.
  • University of ChicagominorStrategic or Co-development PartnerCollaboration with Dr. Aaron Esser-Kahn on discovering novel combination adjuvants. Academic-industry partnership to develop next-generation vaccine adjuvants.
  • University of MontanacoreStrategic or Co-development PartnerCollaboration with Center for Translational Medicine Adjuvant Research Team on multiple projects including opioid vaccine, TRAC478 vaccine adjuvant, and INI-1098 vaccine adjuvant development projects.
  • University of North CarolinacoreStrategic or Co-development PartnerCollaboration with Drs. Mike Kulis and Johanna Smeekens at UNC on development of sublingual food allergy therapy.
  • University of WashingtonminorStrategic or Co-development PartnerCollaboration with Dr. Marco Pravetoni on opioid vaccine development project and Dr. Michael Gale on early-stage adjuvant discovery project.
  • Medical University of ViennacoreStrategic or Co-development PartnerEuropean consortium led by Medical University of Vienna to develop next-generation intranasal influenza vaccine. Consortium aims to be selected under EU4Health programme with budget of EUR 147,951,410. Inimmune contributes proprietary adjuvant INI-4001 and formulation expertise.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Inimmune competitors and assessment

Company assessment

Direct peers

  • Dynavax Technologies: Dynavax is a commercial-stage biopharmaceutical company focused on vaccines and adjuvants, with the CpG 1018 TLR9 adjuvant platform used in approved COVID and hepatitis B vaccines. Most directly comparable to Inimmune's TLR-based adjuvant business and vaccine development focus.
  • Adjuvance Technologies: Adjuvance Technologies is a privately-held biotechnology company developing saponin-based adjuvants including TQL1055, a next-generation semi-synthetic saponin. Directly competes with Inimmune's T4Q (TLR4 + QS21 saponin) and T4AH adjuvant systems in the vaccine adjuvant market.
  • Selecta Biosciences: Selecta Biosciences (now Cartesian Therapeutics) developed immune tolerance therapies and novel adjuvants using nanoparticle technology. Comparable to Inimmune in focusing on innate immune modulation and tolerogenic immunotherapies, though focused on autoimmune applications.
  • Intrommune Therapeutics: Intrommune Therapeutics is a clinical-stage biotech developing INT301 oral mucosal immunotherapy for peanut and other food allergies. Direct partner with Inimmune combining INI-2004 with INT301 for next-generation allergy treatment.

Emerging players

  • Checkmate Pharmaceuticals: Checkmate Pharmaceuticals developed CMP-001, a TLR9 agonist intratumoral therapy for melanoma before being acquired by Regeneron in 2022. Directly relevant precedent for TLR agonist development in oncology immunotherapy, similar to Inimmune's INI-4001 program.
  • Bolt Biotherapeutics: Bolt Biotherapeutics developed immune-stimulating antibody conjugates (ISACs) targeting innate immunity for cancer treatment. Comparable clinical-stage oncology immunotherapy company using novel immune activation approaches, though with different mechanism than Inimmune's TLR agonists.
  • CureVac: CureVac is a clinical-stage biopharmaceutical company developing mRNA-based vaccines and immunotherapies with proprietary adjuvant approaches. Comparable clinical-stage biotech developing novel vaccine technology, though using different mRNA platform.

Broad incumbents

  • GSK (GlaxoSmithKline): GSK is a global pharmaceutical leader with the established AS01, AS04, and other proprietary adjuvant systems used in Shingrix, Cervarix, and other vaccines. Inimmune's founders came from GSK Vaccines and compete directly in the adjuvant space with this industry incumbent.
  • Novavax: Novavax develops recombinant protein vaccines using its proprietary Matrix-M saponin-based adjuvant, comparable to Inimmune's T4Q and T4AH adjuvant systems. Broad incumbent in the vaccine adjuvant and development space.
  • Stallergenes Greer: Stallergenes Greer is a global leader in allergen immunotherapy (AIT) for respiratory allergies, offering subcutaneous and sublingual treatments. Competes in the allergy immunotherapy market where Inimmune's INI-2004 is positioned as a disease-modifying alternative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Inimmune social profiles

Digital presence

Inimmune financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inimmune leadership team

Management profile

Number of profiles

Profiles16 records

Inimmune funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inimmune M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inimmune

What does Inimmune do?

Inimmune is a clinical-stage biotechnology company developing a portfolio of disease-modifying immunotherapies and vaccine adjuvants based on proprietary Toll-like receptor (TLR) agonist technology. The company focuses on innate immune system modulation, with clinical-stage assets including INI-2004 (TLR4 agonist for allergic rhinitis) and INI-4001 (TLR7/8 agonist for cancer immunotherapy), plus advanced adjuvant systems (T4Q, T4AH, TRAC478, INI-1098) and vaccine candidates targeting opioid use disorder and infectious diseases.

Is Inimmune a public or private company?

Inimmune is a private company. It is classified as venture growth investor backed and is currently operating.

When was Inimmune founded?

Inimmune was founded in 2016. It employs 11 to 50 people.

Where is Inimmune based?

Inimmune is headquartered in Missoula, United States, in the North America region.

How does Inimmune make money?

One revenue line is on record: licensing and Co-development Agreements.

Who are Inimmune's main competitors?

Direct peers on record are Dynavax Technologies, Adjuvance Technologies, Selecta Biosciences and Intrommune Therapeutics. Emerging players are Checkmate Pharmaceuticals, Bolt Biotherapeutics and CureVac. Broad incumbents are GSK (GlaxoSmithKline), Novavax and Stallergenes Greer.

Does Inimmune have an API?

No public API is recorded for Inimmune.

What industry is Inimmune in?

Inimmune's product category is Biopharmaceutical Immunotherapeutics. Its primary akta.pro industry code is HLAIAEAI, Vaccine Adjuvants & Formulation Systems, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comTop Companies and Competitive Dynamics in the Allergy Immunotherapy MarketThe allergy immunotherapy market is projected to grow to $5.64 billion by 2030 with a compound annual growth rate of 12.2%, driven by personalized treatments, expanded pediatric care access, and increased research investment. In January 2024, U.S.-based biotechnology firm Inimmune Corporation announced a strategic partnership with Intrommune Therapeutics, Inc. to develop a next-generation oral mucosal immunotherapy for peanut allergy treatment. A separate November 2023 development involved BioIntelliSense launching a continuous monitoring program with UC Davis Health for bone marrow transplant recipients.BioSpaceInimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic RhinitisInimmune Corporation announced the completion of enrollment and dosing of the first patient in its Phase 2 allergen challenge chamber trial evaluating INI-2004, an investigational immunotherapy for allergic rhinitis. The randomized, placebo-controlled trial will evaluate safety, tolerability, and efficacy of INI-2004, which targets toll-like receptor 4 (TLR4) pathways to rapidly reprogram immune responses to allergens. Topline data from the study is expected in June 2026, with the company planning to engage regulatory authorities afterward to determine the path for late-stage development and potential expansion into food allergies, allergic asthma, and other atopic conditions.PR NewswireInimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic RhinitisInimmune Corporation announced the completion of enrollment and dosing of the first patient in its Phase 2 allergen challenge chamber trial evaluating INI-2004, an investigational immunotherapy for allergic rhinitis. The randomized, placebo-controlled trial will evaluate safety, tolerability, and efficacy of INI-2004, which targets innate immune pathways to potentially deliver a disease-modifying effect across multiple allergen types. Topline data from the study is expected in June 2026.The Missoula Current NewsMissoula-based Inimmune names CMO, head of financial strategyA biotech company, Inimmune, based in Missoula, appointed Ferdinand Massari as the new chief medical officer and Ryan McMillian as the head of financial strategy. This move is aimed at strengthening the leadership team as the company advances its pipeline and plans to expand into allergic asthma and food allergy. The appointments come at a crucial time for Inimmune as it seeks to execute its growth strategy and develop innovative immunotherapies for patients.PR NewswireInimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data ReadoutInimmune Corporation announced the appointments of Ferdinand Massari, M.D. as Chief Medical Officer and Ryan McMillian as Head of Financial Strategy to strengthen its leadership team ahead of Phase 2 data readout for its lead allergic rhinitis program INI-2004. Dr. Massari brings over two decades of clinical development experience in immunology and inflammatory diseases from prior roles at Shire, Pfizer, and Merck, while McMillian brings over 20 years of biotech finance experience including over $250 million in fundraising for life sciences companies. The new appointments support Inimmune's strategic expansion into allergic asthma and food allergy, conditions affecting millions worldwide.PR NewswireInimmune Commences Pivotal Phase 2 Allergy Trial of INI-2004 in Allergic Rhinitis PatientsInimmune Corporation announced the commencement of its pivotal Phase 2 clinical trial for INI-2004, a novel immunotherapy for allergic rhinitis, being conducted in Kingston, Ontario, Canada. The randomized, double-blind, placebo-controlled trial will evaluate efficacy and safety through Total Nasal Symptom Score improvement in patients exposed to controlled ragweed allergen challenge conditions, with enrollment starting this month and topline results expected in late May 2026. The company also plans to expand into a food allergy clinical trial with INI-2004 in early 2027.Venture Capital Access OnlineInimmune raises $22 Million in Series A Funding Led by Two Bear CapitalInimmune, a Missoula-based biotechnology company, raised $22 million in its first Series A funding round led by Two Bear Capital. The company intends to use the capital to advance late-stage pre-clinical drug candidates in oncology and allergy through Phase I human clinical trials. This investment supports Inimmune's ongoing efforts to develop immune therapies and vaccines for various diseases.InimmuneInsilico Medicine and Inimmune Achieved collaboration to Revolutionize Immunotherapy with AI-Driven Drug DiscoveryInsilico Medicine announced on September 13, 2024 that it has partnered with Inimmune to use Chemistry42, its proprietary multi-agent reinforcement learning system, to accelerate discovery of next-generation immunotherapeutics. Inimmune used the platform to generate and screen template molecules, evaluating metabolic stability, synthetic difficulty and ADME properties, and plans two to three more rounds of optimization. No financial terms were disclosed.News-MedicalInsilico Medicine partners with Inimmune to advance immunotherapeutic discoveryInsilico Medicine partnered with Inimmune to use its Chemistry42 AI platform for discovering immunotherapeutics. The collaboration generated novel template molecules and evaluated properties like metabolic stability and ADME, leading to high-potential hit series. Inimmune plans 2-3 rounds of optimization to refine lead compounds for synthesis and testing.